Anzeige
Mehr »
Sonntag, 28.09.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken hat sich bewiesen - und American Critical sitzt direkt auf dem nächsten Milliardenfund
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JS1K | ISIN: IE00B4Q5ZN47 | Ticker-Symbol: J7Z
Tradegate
25.09.25 | 18:51
108,65 Euro
+0,09 % +0,10
1-Jahres-Chart
JAZZ PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
JAZZ PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
107,70109,4517:20
108,30108,8026.09.

Aktuelle News zur JAZZ PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiDeep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)1
JAZZ PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiJazz Pharmaceuticals stock price target raised to $167 from $163 at Morgan Stanley3
DiJazz Pharmaceuticals: Morgan Stanley erhöht Kursziel auf 167 US-Dollar4
MoJazz Pharma: Positive Studienergebnisse für Narkolepsie-Mittel Xywav1
MoJazz Pharmaceuticals plc: Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych ...8220 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine Novel results from the Phase 4 DUET trial underscore...
► Artikel lesen
15.09.Piper Sandler reiterates Overweight rating on Jazz Pharmaceuticals stock1
11.09.Amneal wins FDA nod for generic targeting Jazz Pharma's Xyrem2
09.09.Jazz Pharmaceuticals plc: Modeyso (dordaviprone) Included in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma208Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United States For U.S. media and investors...
► Artikel lesen
28.08.Jazz Pharmaceuticals stock price target raised to $205 by Truist Securities12
28.08.RBC Kapital erhöht Kursziel für Jazz Pharmaceuticals auf 151 US-Dollar2
28.08.Jazz Pharmaceuticals stock price target raised to $151 by RBC Capital2
28.08.Jazz Pharmaceuticals stock rises as Stifel reiterates Buy rating on Modeyso launch2
21.08.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference561DUBLIN, Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company management...
► Artikel lesen
21.08.Jazz Pharmaceuticals verfehlt Gewinnprognose für Q2 2025 - Aktie bricht ein8
21.08.Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug3
20.08.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Host Modeyso (dordaviprone) Investor Webcast on August 27, 2025333DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an overview...
► Artikel lesen
20.08.Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement2
20.08.Jazz Pharmaceuticals enters exclusive licensing deal with Saniona5
20.08.Jazz Pharmaceuticals Enters Into Global License Agreement To Develop SAN2355300WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ), Wednesday announced a global license agreement with Denmark-based Saniona to obtain exclusive worldwide rights to develop SAN2355, a preclinical...
► Artikel lesen
20.08.FDA approves Jazz Pharmaceuticals' Modeyso as first drug for ultra-rare brain cancer4
Weiter >>
106 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1